Blackpool CCG medicines optimisation

Blackpool CCG medicines optimisation

Medicines play an important part in promoting well-being, preventing ill health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines management can be defined in several ways:

  • The clinical, cost-effective, safe and secure handling of medicines
  • A system of processes and behaviours that determines how medicines are used by the NHS and patients
  • Enabling people to make the best possible use of medicines
  • Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s medicines management team on 01253 951306 or email


Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

28 Day Prescribing 0.3 MB268
Camouflaging Products 0.2 MB86
Cannabis based medicinal products for pain POSITION STATEMENT 0.3 MB225
Clinical Need Low Priority Medicines - General 0.3 MB366
Clinical Need Soluble Analgesics 0.5 MB559
Clinical Need Thickeners Position Statement 0.3 MB299
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB189
Denosumab Position Statement 0.3 MB183
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB218
Edoxaban Position Statement 0.2 MB199
Emollients and Sunscreens 0.2 MB324
Free of Charge (FOC) Medicines schemes 0.3 MB202
Generic Biosimilar Medicines Position Statement 0.2 MB196
Generic Prescribing Guidelines 0.3 MB312
Glucose Monitoring Devices 0.5 MB257
Gluten Free Foodstuffs 0.2 MB207
Health Professionals e-cigarettes briefing 0.2 MB170
Holiday Medication 0.2 MB311
Liothyronine 0.2 MB193
Ophthalmology Macular Pathways 1.1 MB190
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB263
Out of Area Prescribing 0.2 MB150
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB218
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB84
Position Statement Sip Feeds 0.4 MB221
Prescribing Nutritional Supplements Post Bariatric Surgery 0.3 MB195
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB171
Prescribing Vitamins And Minerals 0.3 MB174
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB162
Stoma Care Products - deodorants and air fresheners 0.4 MB228
Trans Anal Irrigation Devices 0.2 MB172
Vitamin D Position Statement 0.2 MB130
Zero Risk Schemes 0.3 MB166

Prescribing guidance

Asthma treatment guideline for children version 0.4 MB84
Axial-Spondyloarthritis-pathway-Version 37 KB129
Blood glucose meters and test strips Type 2 Diabetes V2.3 0.5 MB554
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB184
Chronic Non-cancer Pain Guidelines 0.7 MB175
Colomycin prescribing information sheet Non CF indications. 0.2 MB146
Constipation-Pathway-Version 0.7 MB602
dementia medicines information sheet 0.3 MB69
Diabetes - Glucagon Like Peptide Contract 0.2 MB211
Diabetes - Home Monitoring of Blood Glucose Levels Guideline 0.2 MB395
DIABETES Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[1] 0.5 MB203
Diabetes-self-management-contract 0.5 MB239
Edoxaban Prescribing Tip 68 KB243
Erectile-Dysfunction-Guideline-Version 1.0 MB261
Flash Glucose Monitoring policy - L&SC 0.2 MB160
Gastroenterology-Biologics-Pathway-Version 0.4 MB212
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB170
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB386
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB124
Headache Management Guideline for Adults 0.7 MB153
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB192
Interim Gender Dysphoria protocol 0.6 MB159
Lancashire and South Cumbria Self-Care and Acces to OTC Medicines – Temp... 83 KB75
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB935
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB80
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB200
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB334
Neuropathic Pain Guidance (Version 1.2) 0.9 MB272
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB195
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB162
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB265
Primary Care Good Prescribing Guide 0.6 MB520
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB173
Psoriasis LMMG Biologic and High Cost Drug Commissioning Pathway v-1.6[1] 0.4 MB263
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB232
RA-High-Cost-Drugs-Pathway-v 0.2 MB194
Restless Legs Syndrome guidelines 0.3 MB136
Rheumatoid Arthritis Pathway Guideline 0.1 MB82
SIP Feeds 0.1 MB242
Trans male prescribing information sheet 0.2 MB111
Trans-female-gender-dysphoria-prescribing-information-sheet-version-1.1[1] 0.2 MB81
Wound care formulary 8.2 MB376

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document:

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started October 2018
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin)  – Started September 2018
  • Lixiana (Edoxaban) – Started October 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started June 2019
  • Seretide (Fluticasone / Salmeterol) – Started January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started October 2018
  • Xarelto (Rivaroxaban) – Started July 2019
  • Zoladex (Goserelin) – Started January 2019

Last updated on 18 December 2019 at 11:11 by Senior communications and engagement officer N